JO
NPCE icon

John Overdeck’s Neuropace NPCE Stock Holding History

John Overdeck’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$480K Sell
30,192
-43,900
-59% -$706K ﹤0.01% 4190
2026
Q1 		$974K Buy
74,092
+6,000
+9% +$90K ﹤0.01% 3278
2025
Q4 		$1.05M Buy
68,092
+48,799
+253% +$653K ﹤0.01% 2879
2025
Q3 		$199K Sell
19,293
-69,345
-78% -$654K ﹤0.01% 3378
2025
Q2 		$987K Buy
88,638
+56,206
+173% +$703K ﹤0.01% 2257
2025
Q1 		$399K Buy
32,432
+6,286
+24% +$78.7K ﹤0.01% 2613
2024
Q4 		$293K Buy
+26,146
New +$227K ﹤0.01% 2743
2024
Q3 		– Sell
-33,094
Closed -$250K – 3272
2024
Q2 		$250K Buy
+33,094
New +$334K ﹤0.01% 2662

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

John Overdeck's NPCE Position: Q2 2026 in Review

John Overdeck reduced its Neuropace (NPCE) stake by 59% in Q2 2026, selling an estimated $706K and leaving 30,192 shares worth $480K. The position accounts for ﹤0.01% of the portfolio, ranked #4190.

John Overdeck first reported a position in NPCE in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.05M in Q4 2025. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • John Overdeck held 30,192 shares of Neuropace worth $480K as of Q2 2026.
  • John Overdeck sold 43,900 Neuropace shares in Q2 2026, an estimated $706K.
  • Neuropace made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4190 holding.
  • John Overdeck first reported a position in Neuropace in Q2 2024 and has held it in 8 quarters since.
  • John Overdeck's Neuropace position peaked at $1.05M in Q4 2025.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.